The Pune-headquartered company, a subsidiary of Emcure Pharmaceuticals, had received approval in December last year to start phase 1 and 2 trials for its COVID-19 vaccine candidate. However, it got delayed as the Drugs Controller General of India (DGCI) asked the company to repeat the animal toxicity study which it had conducted in the US.

Leave a Reply

Your email address will not be published. Required fields are marked *